Disclosed is a compound of formula I, and pharmaceutically acceptable salts thereof, wherein the substituents are as described within the specification. An example of a compound of formula I includes: N-[2-(dimethylamino)ethyl]-5-fluoro-2-methyl-1-[{ 4-methylsulfmyl)phenyl]methylene]-1H-indene-3-acetamide. Further disclosed is the use of a compound of formula I in the manufacture of a medicament for treating a pre-cancerous condition or a cancer in a mammal, and a method for preparing a compound of formula I which comprises reacting sulindac with a represented by the formula: NH2(CH2)mNR1R2, Wherein the substituents are as described within the specification.
